Dapagliflozin Alliance Targets Surging Indian Diabetes Market

AstraZeneca has struck an agreement with India’s Sun Pharma under which the two companies will promote and distribute the UK-based firm’s diabetes drug dapagliflozin under different brand names. The deal means AstraZeneca can benefit from Sun’s wide distribution network to penetrate India’s rapidly growing diabetes sector while retaining intellectual property rights.